CY1110551T1 - Λεντοϊικοι φορεις για την παρασκευη ανοσοθεραπευτικων συνθεσεων - Google Patents
Λεντοϊικοι φορεις για την παρασκευη ανοσοθεραπευτικων συνθεσεωνInfo
- Publication number
- CY1110551T1 CY1110551T1 CY20091101210T CY091101210T CY1110551T1 CY 1110551 T1 CY1110551 T1 CY 1110551T1 CY 20091101210 T CY20091101210 T CY 20091101210T CY 091101210 T CY091101210 T CY 091101210T CY 1110551 T1 CY1110551 T1 CY 1110551T1
- Authority
- CY
- Cyprus
- Prior art keywords
- retroviral
- response
- cytotoxic
- cis
- transcriptional
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000001177 retroviral effect Effects 0.000 abstract 5
- 230000002103 transcriptional effect Effects 0.000 abstract 2
- 108700019146 Transgenes Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/867—Retroviral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Η εφεύρεση αφορά σε μία ανοσογονική σύνθεση που περιέχει ένα ανασυνδυασμένο φορέα που χαρακτηρίζεται από το ότι περιέχει ένα πολυνουκλεοτίδιο που περιέχει την σε διαμόρφωση cis δρώσα κεντρική περιοχή έναρξης (cPPT) και την σε cis διαμόρφωση δρώσα περιοχή λήξης (CTS), οι περιοχές αυτές είναι ρετροϊικής ή τύπου ρετροϊικής προέλευσης, ο εν λόγω φορέας περιλαμβάνει επίσης μία καθορισμένη νουκλεοτιδική αλληλουχία (διαγονιδιακή ή αλληλουχία που ενδιαφέρει) και ρυθμιστικά σήματα ανάδρομης μεταγραφής, έκφρασης και εγκαψιδίωσης ρετροϊικής ή τύπου ρετροϊικής προέλευσης, όπου η σύνθεση είναι ικανή να επάγει ή να διεγείρει μία απόκριση με διαμεσολάβηση κυττάρων για παράδειγμα μία απόκριση CTL (Κυτταροτοξικά L Λεμφοκύτταρα, Cytotoxic Τ Lymphocytes) ή μία απόκριση CD4, έναντι ενός ή πολλών επιτόπων που κωδικοποιούνται από την διαγονιδιακή αλληλουχία που υπάρχει στον φορέα.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99402492A EP1092779B1 (en) | 1999-10-11 | 1999-10-11 | Lentiviral vectors for the preparation of immunotherapeutical compositions |
EP06001198A EP1650309B1 (en) | 1999-10-11 | 2000-10-10 | Lentiviral vectors for the preparation of immunotherapeutical compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1110551T1 true CY1110551T1 (el) | 2015-04-29 |
Family
ID=8242139
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20061101129T CY1105149T1 (el) | 1999-10-11 | 2006-08-10 | Λεντοϊκοι φορεις για την παρασκευη ανοσοθepαπευτικων συνθεσεων |
CY20091101210T CY1110551T1 (el) | 1999-10-11 | 2009-11-24 | Λεντοϊικοι φορεις για την παρασκευη ανοσοθεραπευτικων συνθεσεων |
CY20101100155T CY1110611T1 (el) | 1999-10-11 | 2010-02-17 | Λεντοϊκοι φορεις για την παρασκευη ανοσοθεραπευτικων συνθεσεων |
CY20141100100T CY1114819T1 (el) | 1999-10-11 | 2014-02-06 | Φορεας για την παρασκευη ανοσοθεραπευτικων συνθεσεων |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20061101129T CY1105149T1 (el) | 1999-10-11 | 2006-08-10 | Λεντοϊκοι φορεις για την παρασκευη ανοσοθepαπευτικων συνθεσεων |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20101100155T CY1110611T1 (el) | 1999-10-11 | 2010-02-17 | Λεντοϊκοι φορεις για την παρασκευη ανοσοθεραπευτικων συνθεσεων |
CY20141100100T CY1114819T1 (el) | 1999-10-11 | 2014-02-06 | Φορεας για την παρασκευη ανοσοθεραπευτικων συνθεσεων |
Country Status (15)
Country | Link |
---|---|
US (3) | US7968332B2 (el) |
EP (4) | EP1092779B1 (el) |
JP (2) | JP4663943B2 (el) |
CN (2) | CN1840204B (el) |
AT (3) | ATE449858T1 (el) |
AU (3) | AU785060B2 (el) |
CA (1) | CA2387182C (el) |
CY (4) | CY1105149T1 (el) |
DE (3) | DE69941703D1 (el) |
DK (4) | DK1092779T3 (el) |
ES (4) | ES2447115T3 (el) |
HK (2) | HK1093523A1 (el) |
IL (2) | IL148901A0 (el) |
PT (4) | PT1092779E (el) |
WO (1) | WO2001027300A1 (el) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2777909B1 (fr) | 1998-04-24 | 2002-08-02 | Pasteur Institut | Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex |
ES2447115T3 (es) | 1999-10-11 | 2014-03-11 | Institut Pasteur | Vectores para la preparación de composiciones inmunoterapéuticas |
DE60033045T2 (de) * | 1999-10-12 | 2007-11-08 | Institut Pasteur | Lentivirale triplex-dns, und vektoren und rekombinante zellen, die lentivirale triplex-dns enthalten |
US7575924B2 (en) | 2000-11-13 | 2009-08-18 | Research Development Foundation | Methods and compositions relating to improved lentiviral vectors and their applications |
AU2002327412A1 (en) | 2001-08-02 | 2003-02-17 | Institut Clayton De La Recherche | Methods and compositions relating to improved lentiviral vector production systems |
NZ532060A (en) | 2001-10-02 | 2005-11-25 | Inst Clayton De La Rech | Methods and compositions relating to restricted expression lentiviral vectors and their applications |
FR2870126B1 (fr) * | 2004-05-17 | 2009-07-17 | Pasteur Institut | Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin |
EP1712241A1 (en) | 2005-04-15 | 2006-10-18 | Centre National De La Recherche Scientifique (Cnrs) | Composition for treating cancer adapted for intra-tumoral administration and uses thereof |
US8222029B2 (en) | 2005-05-16 | 2012-07-17 | Institut Pasteur | Lentiviral vector-based vaccine |
US8158413B2 (en) * | 2005-10-17 | 2012-04-17 | Institut Pasteur | Lentiviral vector-based vaccine |
EP1739092A1 (en) | 2005-06-28 | 2007-01-03 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Peptidic antagonists of class III semaphorins/neuropilins complexes |
EP1748067A1 (en) | 2005-07-29 | 2007-01-31 | Institut Pasteur | Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes |
EP1948215B1 (en) | 2005-11-14 | 2012-01-11 | Centre National De La Recherche Scientifique (Cnrs) | MacroH2A non-histone domain as inhibitor of PARP-1 activity and uses thereof |
ES2654303T3 (es) | 2007-05-04 | 2018-02-13 | University Health Network | Inmunoterapia de IL-12 contra el cáncer |
BRPI0813194B8 (pt) * | 2007-08-03 | 2021-05-25 | Centre Nat Rech Scient | kit, partículas de vetor lentiviral, composição de vetores plasmídicos, antígeno derivado de hiv-1 quimérico, proteína de envelope de vsv-g, moléculas de ácido nucleico, composição imunogênica e uso de um vetor lentiviral |
EP2385107B1 (en) | 2010-05-03 | 2016-08-24 | Institut Pasteur | Lentiviral vector based immunological compounds against malaria |
EP2666477A1 (en) | 2012-05-23 | 2013-11-27 | Theravectys | Lentiviral vectors containing an MHC class I promoter |
CN105821078A (zh) | 2010-12-09 | 2016-08-03 | 巴斯德研究所 | 用于获得高产量重组蛋白表达的基于mgmt的方法 |
CA2857998C (en) | 2011-12-09 | 2021-01-19 | Institut Pasteur | Multiplex immuno screening assay |
US20150182617A1 (en) | 2012-07-25 | 2015-07-02 | Theravectys | Glycoproteins for pseudotyping lentivectors |
EP3009144A1 (en) | 2014-10-15 | 2016-04-20 | Theravectys | Lentiviral vectors for inducing CD4+ and CD8+ immune responses in vaccination of humans |
WO2015063706A1 (en) | 2013-10-31 | 2015-05-07 | Theravectys | Lentiviral vectors for expression of hiv-1 antigens |
US10538785B2 (en) | 2013-12-23 | 2020-01-21 | Renaud Vaillant | Lyophilized lentiviral vector particles, compositions and methods |
SG11201606148UA (en) | 2014-01-27 | 2016-08-30 | Theravectys | Lentiviral vectors for generating immune responses against human t lymphotrophic virus type 1 |
GB201408255D0 (en) * | 2014-05-09 | 2014-06-25 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML) |
EP3172228B1 (en) | 2014-07-25 | 2019-02-27 | Theravectys | Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule |
EP3031923A1 (en) | 2014-12-11 | 2016-06-15 | Institut Pasteur | Lentiviral vector-based japanese encephalitis immunogenic composition |
WO2017134265A1 (en) | 2016-02-05 | 2017-08-10 | Institut Pasteur | Use of inhibitors of adam12 as adjuvants in tumor therapies |
EP3211003A1 (en) | 2016-02-24 | 2017-08-30 | Institut Pasteur | T cell receptors from the hiv-specific repertoire, means for their production and therapeutic uses thereof |
EP3276006A1 (en) | 2016-07-27 | 2018-01-31 | Theravectys | Lentiviral vectors for expression of hepatitis b virus (hbv) antigens |
EP3357504A1 (en) | 2017-02-02 | 2018-08-08 | Institut Pasteur | Functional screening of antigenic polypeptides - use for the identification of antigens eliciting a protective immune response and for the selection of antigens with optimal protective activity |
EP3357506A1 (en) | 2017-02-02 | 2018-08-08 | Institut Pasteur | Multiple malaria pre-erythrocytic antigens and their use in the elicitation of a protective immune response in a host |
EP3648776A4 (en) | 2017-07-06 | 2021-04-07 | The Medical College of Wisconsin, Inc. | NEW IN VITRO AND IN VIVO ENRICHMENT STRATEGY TARGETING CHS-DERIVED LYMPHOCYTES TRANSDUCED BY A VECTOR FOR THE THERAPY OF DISORDERS |
EP3697809A1 (en) | 2017-10-20 | 2020-08-26 | Institut Curie | Dap10/12 based cars adapted for rush |
EP3697811A1 (en) | 2017-10-20 | 2020-08-26 | Institut Curie | Hook fusion protein for regulating the cellular trafficking of a target protein |
CN108118070A (zh) * | 2018-01-15 | 2018-06-05 | 南京驯鹿医疗技术有限公司 | 一种慢病毒制备方法 |
CN108588028B (zh) * | 2018-04-26 | 2021-11-09 | 中国人民解放军军事科学院军事医学研究院 | 一种靶向cdkn2a的cic细胞模型及其制备方法 |
CA3136252A1 (en) | 2019-05-10 | 2020-11-19 | Francesca DI NUNZIO | Live imaging system to visualize the retro-transcribed viral dna genome |
WO2021234110A1 (en) | 2020-05-20 | 2021-11-25 | Institut Curie | Single domain antibodies and their use in cancer therapies |
AU2021308424A1 (en) | 2020-07-15 | 2023-02-09 | Institut Pasteur | SARS-CoV-2 immunogenic compositions, vaccines, and methods |
WO2022167831A1 (en) | 2021-02-02 | 2022-08-11 | Institut Pasteur | Sars-cov-2 immunogenic compositions, vaccines, and methods |
CN117120085A (zh) | 2020-07-15 | 2023-11-24 | 巴斯德研究所 | Sars-cov-2免疫原性组合物、疫苗和方法 |
GB202013940D0 (en) | 2020-09-04 | 2020-10-21 | Synpromics Ltd | Regulatory nucleic acid sequences |
EP4214223A1 (en) | 2020-09-21 | 2023-07-26 | Theravectys | High throughput methods and products for sars-cov-2 sero-neutralization assay |
WO2022076556A2 (en) | 2020-10-07 | 2022-04-14 | Asklepios Biopharmaceutical, Inc. | Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy disorders including limb girdle 2i (lgmd2i) |
EP3984548A1 (en) | 2020-10-16 | 2022-04-20 | Institut Pasteur | Generation of lentiviral vectors enabling routing antigens to mhc-ii pathway and inducing cd4+ and cd8+ t-cell responses immune response in a host |
EP4229090A1 (en) | 2020-10-16 | 2023-08-23 | Université d'Aix-Marseille | Anti-gpc4 single domain antibodies |
IL304031A (en) | 2021-01-14 | 2023-08-01 | Inst Curie | Variants of single-domain HER2 antibodies and their chimeric antigenic receptors |
WO2022189656A1 (en) | 2021-03-12 | 2022-09-15 | Institut Pasteur | Lentiviral vectors targeting antigens to mhc-ii pathway and inducing protective cd8+ and cd4+ t-cell immunity in a host |
AU2022386715A1 (en) | 2021-11-15 | 2024-05-16 | Institut Pasteur | Lentiviral vectors for expression of human papillomavirus (hpv) antigens and its implementation in the treatment of hpv induced cancers |
WO2024023135A1 (en) | 2022-07-27 | 2024-02-01 | Theravectys | Lentiviral vectors for expression of human papillomavirus (hpv) antigens and its implementation in the treatment of hpv induced cancers |
WO2024084041A2 (en) | 2022-10-21 | 2024-04-25 | Institut Pasteur | Polynucleotides and lentiviral vectors expressing non-structural antigens of a flavivirus selected from the group of denv, zikv and yfv, inducing protective cd8+ t-cell immunity in a host |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1038306A (zh) * | 1988-03-21 | 1989-12-27 | 维吉恩公司 | 重组反转录病毒 |
GB9213559D0 (en) * | 1992-06-25 | 1992-08-12 | Smithkline Beecham Biolog | Vaccines |
JPH06261764A (ja) | 1993-02-17 | 1994-09-20 | Wisconsin Alumni Res Found | 混合型ltr含有超複合型レトロウイルス及びその使用方法 |
US6001349A (en) * | 1995-02-22 | 1999-12-14 | Therion Biologics Corporation | Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof |
US6013516A (en) * | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
EP0885302A1 (en) * | 1996-03-05 | 1998-12-23 | The Regents Of The University Of California | Recombinant live feline immunodeficiency virus and proviral dna vaccines |
JP2001513643A (ja) * | 1997-03-06 | 2001-09-04 | ウーベルラ、クラウス | レンチウイルスをベースとするベクター及びベクター系 |
EP1007716A1 (en) | 1997-04-17 | 2000-06-14 | The Regents Of The University Of California | Use of lentiviral vectors for antigen presentation in dendritic cells |
US5891432A (en) * | 1997-07-29 | 1999-04-06 | The Immune Response Corporation | Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same |
ES2217585T3 (es) * | 1997-10-10 | 2004-11-01 | The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | Peptidos agonistas y antagonistas del antigeno carcino-embrionario (cea). |
KR20010015817A (ko) * | 1997-11-14 | 2001-02-26 | 유로-셀티큐 에스.에이. | 항-이디오타입 반응을 유도하는 능력이 강화된 변형된 항체 |
FR2777909B1 (fr) * | 1998-04-24 | 2002-08-02 | Pasteur Institut | Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex |
US7622300B2 (en) * | 1998-06-03 | 2009-11-24 | Kappes John C | Trans-lentiviral vector particles and transduction of eukaryotic cells therewith |
US6555342B1 (en) * | 1998-06-03 | 2003-04-29 | Uab Research Foundation | Fusion protein delivery system and uses thereof |
GB9825524D0 (en) | 1998-11-20 | 1999-01-13 | Oxford Biomedica Ltd | Vector |
ES2447115T3 (es) | 1999-10-11 | 2014-03-11 | Institut Pasteur | Vectores para la preparación de composiciones inmunoterapéuticas |
DE60033045T2 (de) | 1999-10-12 | 2007-11-08 | Institut Pasteur | Lentivirale triplex-dns, und vektoren und rekombinante zellen, die lentivirale triplex-dns enthalten |
US20030194392A1 (en) | 2002-04-10 | 2003-10-16 | Pierre Charneau | Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA |
US8158413B2 (en) | 2005-10-17 | 2012-04-17 | Institut Pasteur | Lentiviral vector-based vaccine |
US8222029B2 (en) | 2005-05-16 | 2012-07-17 | Institut Pasteur | Lentiviral vector-based vaccine |
-
1999
- 1999-10-11 ES ES09176531.3T patent/ES2447115T3/es not_active Expired - Lifetime
- 1999-10-11 EP EP99402492A patent/EP1092779B1/en not_active Expired - Lifetime
- 1999-10-11 DK DK99402492.5T patent/DK1092779T3/da active
- 1999-10-11 DK DK09176531.3T patent/DK2169073T3/da active
- 1999-10-11 EP EP09176531.3A patent/EP2169073B1/en not_active Expired - Lifetime
- 1999-10-11 DE DE69941703T patent/DE69941703D1/de not_active Expired - Lifetime
- 1999-10-11 ES ES99402492T patent/ES2337429T3/es not_active Expired - Lifetime
- 1999-10-11 PT PT99402492T patent/PT1092779E/pt unknown
- 1999-10-11 AT AT99402492T patent/ATE449858T1/de active
- 1999-10-11 PT PT91765313T patent/PT2169073E/pt unknown
-
2000
- 2000-10-10 IL IL14890100A patent/IL148901A0/xx active IP Right Grant
- 2000-10-10 PT PT00972845T patent/PT1222300E/pt unknown
- 2000-10-10 WO PCT/EP2000/010419 patent/WO2001027300A1/en active Application Filing
- 2000-10-10 AU AU11435/01A patent/AU785060B2/en not_active Expired
- 2000-10-10 CN CN2006100045648A patent/CN1840204B/zh not_active Expired - Lifetime
- 2000-10-10 DK DK06001198T patent/DK1650309T3/da active
- 2000-10-10 AT AT06001198T patent/ATE441721T1/de active
- 2000-10-10 PT PT06001198T patent/PT1650309E/pt unknown
- 2000-10-10 JP JP2001530503A patent/JP4663943B2/ja not_active Expired - Lifetime
- 2000-10-10 DE DE60042903T patent/DE60042903D1/de not_active Expired - Lifetime
- 2000-10-10 CN CN008141770A patent/CN1379820B/zh not_active Expired - Lifetime
- 2000-10-10 DE DE60028066T patent/DE60028066T2/de not_active Expired - Lifetime
- 2000-10-10 ES ES06001198T patent/ES2332930T3/es not_active Expired - Lifetime
- 2000-10-10 ES ES00972845T patent/ES2262545T3/es not_active Expired - Lifetime
- 2000-10-10 CA CA2387182A patent/CA2387182C/en not_active Expired - Lifetime
- 2000-10-10 AT AT00972845T patent/ATE326541T1/de active
- 2000-10-10 EP EP00972845A patent/EP1222300B1/en not_active Expired - Lifetime
- 2000-10-10 EP EP06001198A patent/EP1650309B1/en not_active Expired - Lifetime
- 2000-10-10 DK DK00972845T patent/DK1222300T3/da active
-
2002
- 2002-12-06 US US10/313,038 patent/US7968332B2/en not_active Expired - Fee Related
-
2003
- 2003-01-17 HK HK06111332.8A patent/HK1093523A1/xx not_active IP Right Cessation
- 2003-01-17 HK HK03100475.1A patent/HK1049861B/zh not_active IP Right Cessation
-
2006
- 2006-08-10 CY CY20061101129T patent/CY1105149T1/el unknown
- 2006-12-14 AU AU2006252062A patent/AU2006252062B2/en not_active Expired
-
2009
- 2009-11-24 CY CY20091101210T patent/CY1110551T1/el unknown
-
2010
- 2010-02-17 CY CY20101100155T patent/CY1110611T1/el unknown
- 2010-03-24 IL IL204703A patent/IL204703A0/en active IP Right Grant
- 2010-07-21 AU AU2010203111A patent/AU2010203111B2/en not_active Expired
- 2010-11-10 JP JP2010251771A patent/JP5265643B2/ja not_active Expired - Lifetime
-
2011
- 2011-05-10 US US13/104,380 patent/US8349606B2/en not_active Expired - Lifetime
-
2012
- 2012-12-12 US US13/711,898 patent/US8652807B2/en not_active Expired - Fee Related
-
2014
- 2014-02-06 CY CY20141100100T patent/CY1114819T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1110551T1 (el) | Λεντοϊικοι φορεις για την παρασκευη ανοσοθεραπευτικων συνθεσεων | |
CY1112985T1 (el) | Χρηση αλληλουχιων dνα τριπλου ελικα για τη μεταφορα νουκλεοτιδικων αλληλουχιων | |
CY1109978T1 (el) | Αντιγονικα πεπτιδια εξαγομενα απο τελομεραση | |
DK0827509T3 (da) | Modulering af cholesterylestertransferprotein-(CETP)-aktivitet | |
DE69528061T2 (de) | Gereinigte polyporus laccasen und dafür kodierende nukleinsäuren | |
DE3853422D1 (de) | HIV-3-Retrovirus und seine Verwendung. | |
NO165879C (no) | Fremgangsmaate for fremstilling av en invers, stabil mikrolateks. | |
ITRM920350A1 (it) | Epitopi immunologicamente omologhi di hla e proteine del virus hiv. | |
NO870142L (no) | Faserettet sender. | |
FI862683A0 (fi) | Vektorplasmid som laempar sig foer syrningsmedel, speciellt foer mejerisyrningsmedel. | |
NO891372L (no) | Knivklemme til tilkobling av en elektrisk ledning. | |
DE58909339D1 (de) | Humaner Papillomvirus Typ 57, seine DNA und die davon kodierten Proteine. | |
DK62985A (da) | Polypeptid | |
IT1229975B (it) | Coperchi per una migliorata crescita di nastri dendritici. | |
DK0490383T3 (da) | Peptider af HIV-gag-proteinet, fremstilling og anvendelse deraf | |
IT8721267A0 (it) | Copolimero idrolizzato etilene acetato di vinile. | |
FR2592577B1 (fr) | Implant lame adaptable. | |
NO871272D0 (no) | Skjaereklemme for tilkobling av isolerte elektriske ledninger. | |
FI874062A (fi) | Lpv-baserade vaevnadsspecifika virusvektorer och anvaendning av dessa. | |
Sakakibara et al. | Light and IP 3 sensitive Na channel in Hermissenda photoreceptor | |
IT8619987A0 (it) | Tingibordi orizzontale per prodotti di pelletteria, come cinture esimili. | |
IT8601226A0 (it) | Anulare bimetallico cavo aperto. | |
ATE96171T1 (de) | Fuer flagellin kodierende dns und dieses enthaltender vektor. | |
IT209054Z2 (it) | Caffettiera con dispositivo emettitore di vapore. |